糖尿病肾病细胞模型三羧酸循环代谢异常和机制初探

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (5): 481-489.

• 基础研究 • 下一篇

糖尿病肾病细胞模型三羧酸循环代谢异常和机制初探

俞晓忆¹，周芷若²，谢媛¹，孙润彬¹，费菲¹，高浩雪¹，黄京秋¹，阿基业¹，王广基¹

¹中国药科大学药科院药物代谢动力学重点实验室，南京 210046，江苏；²南京中医药大学药学院药效与安全性评价重点实验室，南京 210023，江苏

收稿日期:2017-01-24 修回日期:2017-02-28 出版日期:2017-05-26 发布日期:2017-05-27
通讯作者: 王广基，男，博士，工程院院士，研究方向：药物代谢动力学。 Tel:025-83271128 E-mail：guangjiwang@hotmail.com
作者简介:俞晓忆，男，博士研究生，研究方向：药物代谢动力学。 Tel:13675138271 E-mail：yxyeventually@hotmail.com
基金资助:
江苏省科技计划项目临床医学科技专项 (BL2014070)；国家自然科学基金项目 (81072692)；973“国家重点基础研究发展计划资助”子课题 (2012CB517606)

Preliminary study on mechanism of tricarboxylic acid cycle disruption in diabetic nephropathy cell model

YU Xiaoyi ¹, ZHOU Zhiruo ², XIE Yuan¹, SUN Runbin¹, FEI Fei ¹, GAO Haoxue¹, HUANG Jingqiu¹, A Jiye¹, WANG Guangji¹

¹ Key Laboratory for Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Jiangsu,China; ² National Standard Laboratory of Pharmacology for Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu,China

Received:2017-01-24 Revised:2017-02-28 Online:2017-05-26 Published:2017-05-27

摘要/Abstract

摘要：

目的: 探讨糖尿病肾病（DN）状态下三羧酸（TCA）循环中间代谢产物的差异，观察糖尿病肾病细胞模型中的代谢紊乱。方法: 体外培养人肾小管上皮细胞（HK-2），分为对照组（Control）、高糖组（High glucose）、棕榈酸组（PA）、棕榈酸复合高糖组（PA high glucose）。线粒体染色法观察造模后的细胞损伤状况，基于气相的代谢组学方法检测细胞模型中出现的代谢差异，并找出相关差异化合物。气相色谱-质谱（GC-MS）定量方法进一步测定差异化合物的绝对浓度。qPCR测定差异化合物相关通路的酶表达。结果: 12、24 h内高糖对HK-2细胞的损伤和代谢影响较弱，而棕榈酸在短期内就可以造成肾脏细胞损伤和代谢紊乱，复合因素下的诱导效果更甚。造模细胞内出现的代谢异常中TCA循环占主要部分，其中柠檬酸和琥珀酸水平出现异常升高。并且琥珀酸水平异常主要由其合成酶影响导致。结论: 棕榈酸诱导引起细胞中TCA循环代谢异常变化可能与DN相关。

关键词: 糖尿病肾病, 人肾小管上皮细胞, 棕榈酸, 琥珀酸

Abstract:

AIM: To explore the difference of tricarboxylic acid cycle (TCA) intermediates levels between diabetic nephropathy (DN) model cells and normal HK-2 cells and the metabolic disruption of DN model. METHODS: HK-2 cells were cultured in vitro and were divided into normal group, glucose group, palmitic acid(PA) group, PA high glucose group. Kidney cell damage was observed by fluorescence microscopy after mitochondrial staining. Metabolic disruption was evaluated by a GC-MS based metabolomics method. Concentration of TCA intermediates was measured by a GC-MS based quantification method. Expressions of relative enzymes were measured by qPCR method. RESULTS:High glucose did not exert as strong an effect on cell damage or metabolic disruption as PA, which caused obvious cell damage or metabolic disruption in a short period. The combined inducement presented the strongest effect. TCA intermediates variation was the main change in PA caused HK-2 cells metabolic disruption. Further, PA could increase the level of citrate and succinate in HK-2 cells. And instead of SDH in model cell, the increase of succinate level was closely related to succinate-CoA ligase. CONCLUSION: Metabolic disruption of TCA induced by PA may be closely related to diabetic nephropathy.

Key words: diabetic nephropathy, HK-2, palmitic acid, succinate

中图分类号:

R965.2

俞晓忆，周芷若，谢媛，孙润彬，费菲，高浩雪，黄京秋，阿基业，王广基. 糖尿病肾病细胞模型三羧酸循环代谢异常和机制初探[J]. 中国临床药理学与治疗学, 2017, 22(5): 481-489.

YU Xiaoyi, ZHOU Zhiruo, XIE Yuan, SUN Runbin, FEI Fei, GAO Haoxue, HUANG Jingqiu, A Jiye, WANG Guangji. Preliminary study on mechanism of tricarboxylic acid cycle disruption in diabetic nephropathy cell model[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 481-489.

参考文献

［1］Boddana P, Caskey F, Casula A, et al. UK Renal Registry 11th Annual Report (December 2008): Chapter 14 UK renal registry and international comparisons［J］. Nephron Clin Pract, 2009, 111 (Suppl 1): p.c269-276.
［2］Collins A, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States［J］. Am J Kidney Dis, 2005,45(1 Suppl 1): A5-7,S1-280.
［3］Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China［J］. N Engl J Med, 2010,362(12):1090-1101.
［4］卞丽丽, 尚文斌. 中西医联合治疗糖尿病肾病［J］. 长春中医药大学学报, 2015, 31(1): 64-67.
［5］黎晶晶, 汪悦. 糖尿病肾病中医病因病机［J］. 长春中医药大学学报, 2013,29(3): 449-450.
［6］McDonald I, Thomas L, Millett R, et al. CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records［J］. Am J Kidney Dis, 2015, 66(1): 60-68.
［7］Global status report on noncommunicable diseases［R］. 2014, WHO: Geneva.
［8］Araki S, Haneda M, Koya D, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes［J］. Diabetes, 2007, 56(6): 1727-1730.
［9］Brenner M, Cooper E, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy［J］. N Engl J Med, 2001, 345(12): 861-869.
［10］Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy［J］. J Am Soc Nephrol, 2012, 23(6): 1108-1116.
［11］Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort［J］. Kidney Int, 2004, 65(5): 1870-1876.
［12］Mallamaci F, Ruggenenti P, Perna A, et al. ACE inhibition is renoprotective among obese patients with proteinuria［J］. J Am Soc Nephrol, 2011, 22(6): 1122-1128.
［13］Praga M, Morales E. Obesity, proteinuria and progression of renal failure［J］. Curr Opin Nephrol Hypertens, 2006, 15(5): 481-486.
［14］Futatsugi K, Tokuyama H, Shibata S, et al. Obesity-induced kidney injury is attenuated by amelioration of aberrant PHD2 activation in proximal tubules［J］. Sci Rep, 2016, 6: 36533.
［15］Tang C, J Cai, Dong Z. Mitochondrial dysfunction in obesity-related kidney disease: a novel therapeutic target ［J］. Kidney Int, 2016, 90(5): 930-933.
［16］韩雪玲, 于海涛, 胡丽贞,等. GC-MS方法检测超重/肥胖男性青年血清游离脂肪酸代谢谱［J］. 营养学报, 2013, 35(2): 137-141.
［17］李义龙, 张延, 王萌. 肥胖人群的血清游离脂肪酸水平调查［J］. 中国实验诊断学, 2008, 12(5): 652-654.
［18］Ruggiero C, Elks M, Kruger C, et al. Albumin-bound fatty acids but not albumin itself alter redox balance in tubular epithelial cells and induce a peroxide-mediated redox-sensitive apoptosis［J］. Am J Physiol Renal Physiol, 2014, 306(8): F896-906.
［19］Tanaka Y, Kume S, Araki S, et al. Fenofibrate, a PPARalpha agonist, has renoprotective effects in mice by enhancing renal lipolysis［J］. Kidney Int, 2011, 79(8): 871-882.
［20］Tanifuji C, Suzuki Y, Geot M, et al. Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells［J］. Antioxid Redox Signal, 2005, 7(9/10): 1261-1268.
［21］Yamahara K, Kume S, Koya D, et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions［J］. J Am Soc Nephrol, 2013, 24(11): 1769-1781.
［22］Lim C, Lim K, Han J, et al. Cannabinoid receptor 1 mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells［J］. J Cell Physiol, 2010, 225(3): 654-663.
［23］Singh K, T Singh, Sharma L. Angiotensin (1-7)/Mas receptor axis activation ameliorates the changes in fatty acid composition in diabetic rats with nephropathy［J］. J Exp Pharmacol, 2010, 2: 163-168.
［24］Czajka A, Malik N. Hyperglycemia induced damage to mitochondrial respiration in renal mesangial and tubular cells: Implications for diabetic nephropathy［J］. Redox Biol, 2016, 10: 100-107.
［25］李丹清, 王颖, 周桂玲. 糖尿病肾病大鼠肾小管与肾小球病变的顺序及其意义［J］. 中华糖尿病杂志, 2004, 12(3): 219-224.
［26］彭芳, 伍玉婷, 刘金颖. 肾小管上皮细胞转分化与糖尿病肾病［J］. 北方药学, 2014, 11(2): 70-71.
［27］张政, 彭惠明, 徐晓明. 糖尿病肾病相关微小RNA对高糖下肾小球系膜细胞增殖的影响及其机制［J］. 中国生物制品学杂志, 2010, 23(8): 821-883.
［28］阿基业. 代谢组学数据处理方法-主成分分析［J］. 中国临床药理学与治疗学, 2010, 15(5): 481-489.
［29］曹蓓, 阿基业, 王广基, 等. 代谢组学在临床研究中的应用及进展［J］. 生命科学, 2010, 22(8): 761-771.
［30］赵春艳, 阿基业, 曹蓓, 等. 代谢组学在代谢性疾病研究中的进展［J］. 中国临床药理学与治疗学, 2011, 16(4): 439-446.
［31］Maxwell H, Wiesener S, Chang W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis［J］. Nature, 1999, 399(6733): 271-275.
［32］Sciacovelli M, Goncalves E, Johnson I, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition［J］. Nature, 2016, 537(7621): 544-547.
［33］Selak A, Armour M, MacKenzie D, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase［J］. Cancer Cell, 2005, 7(1): 77-85.
［34］He W, Miao J, Lin C, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors［J］. Nature, 2004, 429(6988): 188-193.
［35］McGettrick F, O'Neill A. How metabolism generates signals during innate immunity and inflammation［J］? J Biol Chem, 2013,288(32): 22893-22898.
［36］Rubic T, Lametschwandtner G, Jost S, et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity［J］. Nat Immunol, 2008, 9(11): 1261-1269.
［37］Tannahill M, Curtis M, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha［J］. Nature, 2013, 496(7444): 238-242.
［38］Tannahill M, O'Neill A. The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3［J］. FEBS Lett, 2011, 585(11): 1568-1572.
［39］Wittenberger T, Schaller C, Hellebrand S. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors［J］. J Mol Biol, 2001, 307(3): 799-813.
［40］Kolseth B, Reine M, Parker K, et al. Increased levels of inflammatory mediators and proinflammatory monocytes in patients with type I diabetes mellitus and nephropathy［J］. J Diabetes Complications, 2017, 31(1): 245-252.
［41］Nissen D, Pajecka K, Stridh H, et al. Dysfunctional TCA-cycle metabolism in glutamate dehydrogenase deficient astrocytes［J］. Glia, 2015, 63(12): 2313-2326.
［42］Olsen M, Sonnewald U. Glutamate: Where does it come from and where does it go［J］? Neurochem Int, 2015, 88: 47-52.

[1]	汤紫照, 聂方钦, 晏欣, 符阳霞, 黄珺, 汪霞, 郭韧. Atglistatin对棕榈酸诱导的血管平滑肌细胞增殖及ATGL表达的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 29-35.
[2]	金依依, 周科挺, 杨成成, 徐萍, 朱素燕. 蛇床子素抑制NF-κB和p38/MAPK改善糖尿病诱导的肾脏损伤[J]. 中国临床药理学与治疗学, 2022, 27(6): 622-631.
[3]	陈倩, 王亚峰, 朵德龙, 常亚娥, 严英俊, 段坤坤. 琥珀酸曲格列汀对2型糖尿病小鼠肠道菌群的改变[J]. 中国临床药理学与治疗学, 2022, 27(1): 15-24.
[4]	王晖, 崔畅, 杨双, 姚安, 吴淑婷, 阳晓燕, 叶玲, 邹志, 唐智, 阳国平, 黄洁, 欧阳冬生. 琥珀酸索利那新片在中国健康受试者的生物等效性研究#br#[J]. 中国临床药理学与治疗学, 2021, 26(3): 299-304.
[5]	徐甜甜, 吴相尧, 皮爱文, 柴惠, 张斌, 王邦才, 窦晓兵, 朱林文思. 丹酚酸A抑制TLR4/JNK MAPK改善棕榈酸诱导的心肌细胞损伤[J]. 中国临床药理学与治疗学, 2021, 26(2): 121-128.
[6]	傅爱, 徐甜甜, 杨贞, 韩强, 窦晓兵, 李松涛. 阿魏酸抑制p38 MAPK保护棕榈酸诱导的肝细胞脂毒性[J]. 中国临床药理学与治疗学, 2021, 26(2): 137-143.
[7]	刘鹏, 赵海玲, 申正日, 王晨, 王昀, 邱新萍, 李平. 糖肾方抑制TGF-β1/Smad3通路促进小鼠肾小管上皮细胞胆固醇流出[J]. 中国临床药理学与治疗学, 2021, 26(1): 1-9.
[8]	赵韶静，曾艳，李正东，张华. 左卡尼汀对大鼠糖尿病肾病的保护作用分析[J]. 中国临床药理学与治疗学, 2019, 24(3): 278-282.
[9]	姚佳，乔迪，郭鑫，崔昌萌. 桑叶中1-脱氧野尻霉素对糖尿病肾病大鼠的治疗作用[J]. 中国临床药理学与治疗学, 2018, 23(5): 517-523.
[10]	姜莉莉，毛利民，胡思佳，彭应枝. 肾衰宁颗粒对糖尿病肾病大鼠肾组织NF-kB及PPAR-gamma表达的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 132-137.
[11]	傅永锦，夏雪怡，张小牧，刘艳波，潘竞锵，吕俊华. 川芎嗪对糖尿病肾病大鼠下调HMGB1表达及降低RAGEs作用[J]. 中国临床药理学与治疗学, 2017, 22(8): 846-851.
[12]	王惠，陈丁丁，叶彬，岳娟娟，张培岩. 丁酸钠对尿毒症大鼠脑组织线粒体呼吸功能的影响[J]. 中国临床药理学与治疗学, 2016, 21(7): 771-776.
[13]	刘庆生，丁滨，窦晓兵，潘然，张福利，丁蕾，桑怡. 基于JNK信号通路探究半胱氨酸在非酒精性脂肪性肝炎发病机制中的作用[J]. 中国临床药理学与治疗学, 2016, 21(4): 366-371.
[14]	贾会玉, 李中南, 陈光亮. 转化生长因子-β₁介导的Smads和MAPKs信号通路在糖尿病肾病中的作用及其抑制剂研究进展[J]. 中国临床药理学与治疗学, 2015, 20(10): 1171-1176.
[15]	范秋灵, 肇晓明, 蒲实, 李卅立, 杨刚, 姜奕, 王力宁. 坎地沙坦不同治疗时机对2型糖尿病KK/Ta小鼠肾脏血管紧张素1型和2型受体表达的影响[J]. 中国临床药理学与治疗学, 2012, 17(6): 627-633.

糖尿病肾病细胞模型三羧酸循环代谢异常和机制初探

Preliminary study on mechanism of tricarboxylic acid cycle disruption in diabetic nephropathy cell model

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价